Drug Profile
Mavacamten - Bristol Myers Squibb/MyoKardia
Alternative Names: BMS-986427; CAMZYOS; Camzyos; CamzyosTM; HCM 1; MAVA-Bristol Myers Squibb/Myokardia; MYK 461; SAR-439152Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator MyoKardia
- Developer Bristol-Myers Squibb; LianBio; MyoKardia
- Class Cardiovascular therapies; Ethylamines; Heart failure therapies; Pyrimidinones; Small molecules
- Mechanism of Action Cardiac myosin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypertrophic cardiomyopathy
- Phase II Heart failure
Most Recent Events
- 25 Mar 2024 Registered for Hypertrophic cardiomyopathy in Hong Kong (PO) prior to March 2024
- 08 Mar 2024 Phase-III clinical trials in Hypertrophic cardiomyopathy (In adolescents, In children) in USA, Spain (PO) (NCT06253221)
- 15 Feb 2024 Bristol-Myers Squibb plans a phase III trial for Hypertrophic cardiomyopathy (In children, In adolescent) in USA, Canada, France, Germany, Ireland, Italy, Spain, the UK and Australia (PO, Capsule) (NCT06253221)